Skip to Main Content
Contribute Try STAT+ Today

The U.S. Supreme Court has agreed to review a case that has significant implications for consumers and drug makers concerning lawsuits that are filed over product warnings.

The case involves hundreds of lawsuits that were filed by women who claim they suffered bone fractures after taking Fosamax, a Merck (MRK) drug used to combat osteoporosis. Last year, a federal appeals court overturned a lower court and decided the lawsuits should proceed, and last month, the U.S. Solicitor General urged the Supreme Court to review the matter.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.